NVCR News and Press, NovoCure Limited From 07/27/22

Awards aim to promote and support innovative research on Tumor Treating Fields to deepen understanding and accelerate the development of new treatment strategies Novocure today announced the recipients of the 4 th Annual AACR-Novocure Grants for Tumor Treating Fields Res...

ShockWave’s disruptive approach within the calcified cardiovascular disease space creates a first-mover advantage offering the opportunity of robust sales growth. ShockWave Medical’s business model looks to “Grow Markets and Take Market Share” targeting an ...

There's a reason why the Rocky movies were so successful: Nearly everybody loves a comeback. That isn't just true in entertainment; investors like comeback stories, too. We asked three Motley Fool contributors to pick beaten-down stocks that they think could soar in the second half ...

Baillie Gifford’s 13F portfolio value decreased from ~$182B to ~$143B this quarter. They increased Affirm Holdings, Coupang, and Ginkgo Bioworks while reducing Petroleo Brasileiro and First Republic Bank. The top three positions are Tesla Motors, Moderna, and Illumina, and ...

The first half of the year is over. And good riddance. The S&P 500 experienced its worst first half in more than 50 years. Most investors saw the values of their holdings plunge. But the stock market won't remain in the doldrums forever. Here are three growth stocks that co...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2022 on Thursday, July 28, 2022, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss the company’s financial re...

Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its phase 2 pilot KEYNOTE-B36 study, conducted in collaboration with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA. KEYNOTE-B36 is designed to evaluate the safety and effectiveness of Tumor Treat...

Shares of Novocure (NASDAQ: NVCR) were plunging 18.5% this week as of the market close on Thursday, according to data from S&P Global Market Intelligence . The company didn't report any news. So what's behind the steep decline? Novocure was a victim of the broader marke...

Steep stock declines are always painful for investors who own the falling stocks. However, such sell-offs can provide great buying opportunities. We asked three Motley Fool contributors to identify stocks that are down 50% or more that you can buy right now. Here's why they picked Gin...

Novocure (NASDAQ:NVCR) and Zai Lab (NASDAQ:ZLAB) said a mid-stage study of their investigational device for Tumor Treating Fields (TTFields) met its main goal in patients with gastric cancer. TTFields are electric fields that are believed to disrupt cancer cell division. The co...